Heterocyclic Adenosine Antagonists for A2A/A2B Immune Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for adenosine receptor inhibitors, particularly those capable of simultaneously inhibiting A2A and A2B receptors, to enhance the effectiveness of immunotherapy treatments for tumors and other diseases.
Innovation Solution
Development of a class of heterocyclic compounds with A2A and/or A2B receptor inhibitory activity, which can be administered alone or in combination with other anti-tumor drugs, especially immune checkpoint inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PDL-1 antibodies are used as single-agent immunotherapy, then certain clinical effects are achieved on various tumors, but the response rate remains low (20%-40%)
Solution Approach 1:
The patent combines PD-1/PDL-1 antibodies with adenosine receptor antagonists (A2A and/or A2B selective) to create a combination therapy regimen. This merging of two different therapeutic mechanisms addresses the low response rate of single-agent immunotherapy by simultaneously blocking immune checkpoint inhibition and adenosine-mediated immunosuppression in the tumor microenvironment.
Solution Approach 2:
The adenosine receptor antagonist compounds developed in this patent exhibit multi-functional properties: they selectively block A2A and/or A2B receptors, enhance anti-tumor immune responses, and can be combined with various immunotherapies. This universality allows the same compound to address multiple aspects of tumor immune evasion through different pathways.
2Ease of operation
If adenosine receptors are activated to maintain immune regulation, then inflammation and immune responses are controlled, but tumor immune tolerance is enhanced and anti-tumor immune responses are suppressed
Solution Approach 1:
The patent employs selective adenosine receptor antagonism rather than non-selective blockade. By specifically targeting A2A and/or A2B receptors while sparing A1 and A3 receptors, the treatment maintains local immune regulation functions where needed while eliminating harmful immunosuppression in the tumor microenvironment. This selective approach preserves beneficial immune control while removing tumor-promoting effects.
Solution Approach 2:
The patent converts the harmful effect of adenosine-mediated immunosuppression into a therapeutic opportunity. By blocking A2A and A2B receptors, the treatment transforms the immunosuppressive tumor microenvironment into an immunologically active state, thereby converting the previously harmful adenosine signaling into a beneficial anti-tumor immune response.
3Reliability
If A2A and A2B receptors are blocked to eliminate tumor immune tolerance, then anti-tumor immune responses are promoted, but the risk of affecting normal immune regulation increases
Solution Approach 1:
The patent uses selective A2A and A2B receptor antagonism to achieve localized therapeutic effects in the tumor microenvironment without broadly disrupting systemic immune regulation. The selective blockade targets specific receptors involved in tumor immune suppression while preserving other adenosine receptor-mediated protective immune functions in healthy tissues.
Solution Approach 2:
The patent changes the selectivity parameter of adenosine receptor blockade by developing compounds with specific affinity for A2A and/or A2B receptors over A1 and A3 receptors. This parameter change enables differential effects: strong blockade of immunosuppressive A2A/A2B receptors in tumors while maintaining regulation through A1/A3 receptors in normal immune tissues.
Data Source
AI summary
A compound represented by formula (I) and a pharmaceutical composition thereof. The compound represented by formula (I) can be used as an adenosine receptor inhibitor, in particular, A2A and/or A2B inhibitors, for example, can be used for preventing or treating diseases related to A2A and/or A2B activity or expression level.